English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

alongside chemotherapy. The full results will be presented at the American Society of Clinical Oncology meeting in June. “We feel like this study strongly suggests that arsenic needs to be part of the initial treatment for patients with [APL],” said Bayard Powell, M.D., of Wake Forest University in Winston-Salem, N.C., principal investigator of the study. “We do not yet have the information to answer whether it is better here [to maintain remission] or better to use as the very fi rst treatment.” But some investigators who have done clinical studies to test the effectiveness of arsenic trioxide as a front-line treatment for APL say that future clinical studies should now focus on its use as a fi rst treatment. Elihu Estey, M.D., and colleagues from the University of Texas M. D. Anderson Cancer Center in Houston administered a combination of arsenic trioxide plus alltrans-retinoic acid (ATRA), a proven treatment for APL, for both the initial phase and postremission phase of therapy in 44 patients with newly diagnosed APL. Nearly all the patients, 39 (89%), achieved complete remission after the initial treatment with ATRA plus arsenic, the authors reported last year in the journal Blood. The results included 96% of low-risk patients and 79% of high-risk patients, who also received chemotherapy to induce remission. None of the low-risk patients had relapsed after 15–24 months’ follow-up, the researchers note, but three of the 15 high-risk patients did relapse. Two of these three relapsed patients achieved a second complete remission with arsenic. While the number of patients was small, Estey said that the results were encouraging. “The next step will be to ask if we need to give chemotherapy at all,” he added. That result could come from much larger, controlled phase III clinical trial now under way in Europe. This trial, sponsored by the Italian cooperative group GIMEMA and the German group DSIL, will compare arsenic plus ATRA to standard anthracycline chemotherapy plus ATRA in newly diagnosed APL patients. “If it turns out idarubicin plus ATRA is better than what we did, then that’s the end of arsenic for newly diagnosed patients,” Estey said. “But if it turns out you can do as well getting ATRA plus arsenic, then I think that will become the new standard.”

Chinese Folk Treatment Reveals Power of Arsenic To Treat Cancer, New Studies Under Way